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Background: Pain is a public health problem, greatly impairing quality of life. Almost 80% of
patients with chronic pain reported that their pain interferes with activities of daily living,
and two thirds reported that the pain causes negative impact on their personal relationships.
The physical and functional disability, whether temporary or permanent, compromises the
professional activity and causes work absenteeism, increasing costs of health systems.
Objectives: The aim of this review is to analyze, based on the literature, the analgesic effect
of  lidocaine administered intravenously for the treatment of chronic pain and to evaluate
the  reduction of pain intensity in patients with chronic pain, focusing on musculoskeletal
and  neuropathic etiology.
Methodology: The method used was a review of the literature, consisting in searching the
scientiﬁc literature on the efﬁcacy of intravenous lidocaine infusion in the treatment of
patients with chronic pain.
Content: Of the 19 studies reviewed, 12 had results that conﬁrm the analgesic effect of intra-
venous lidocaine in patients with chronic pain. Most authors used doses of 5 mg/kg infused
for  30 minutes or more, producing signiﬁcant analgesia with variable duration (minutes to
weeks).
Conclusions: Based on the literature review, it is not possible to uniformly specify the most
effective and safe dose of lidocaine administered intravenously for the treatment of neuro-
pathic or musculoskeletal pain. As for effectiveness, the intravenous infusion of lidocaine as
an  alternative for the treatment of chronic pain of various etiologies seems very promising,but further studies need to be conducted.
© 2014 Elsevier Editora Ltda. All rights reserved.DOI of original article: http://dx.doi.org/10.1016/j.rbr.2014.01.010.
∗ Corresponding author.
E-mail: maifsmr@hotmail.com (M.F. de Souza).
http://dx.doi.org/10.1016/j.rbre.2014.01.002
2255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
r e v b r a s r e u m a t o l . 2 0 1 4;5 4(5):386–392 387
A  ac¸ão  analgésica  da  lidocaína  intravenosa  no  tratamento  da  dor  crônica:
uma  revisão  de  literatura
Palavras-chave:
Lidocaína
Lidocaína intravenosa
Dor crônica
r  e  s  u  m  o
Justiﬁcativa: A dor é um problema de saúde pública, comprometendo sobremaneira a qual-
idade de vida. Quase 80% dos pacientes com dor crônica relataram que a dor interfere em
suas  atividades da vida diária, e dois terc¸os aﬁrmaram que a dor provoca impacto negativo
nas relac¸ões pessoais. A incapacidade física e funcional, seja temporária ou permanente,
compromete a atividade proﬁssional e causa absenteísmo ao trabalho, elevando os custos
dos sistemas de saúde.
Objetivos: O objetivo desta revisão é analisar, com base na literatura, o efeito analgésico da
lidocaína administrada por via intravenosa no tratamento da dor crônica e avaliar a reduc¸ão
da intensidade da dor em pacientes com dor crônica, focando a etiologia musculoesquelética
e  neuropática.
Metodologia: O método adotado foi o de revisão da literatura, consistindo na busca de artigos
cientíﬁcos sobre a eﬁcácia da infusão intravenosa de lidocaína no tratamento de pacientes
com dor crônica.
Conteúdo: Dos 19 estudos revisados, 12 apresentaram resultados que conﬁrmam a ac¸ão
analgésica da lidocaína por via intravenosa em pacientes com dor crônica. A maioria dos
autores utilizou doses de 5 mg/kg infundidas por 30 minutos ou mais, produzindo analgesia
signiﬁcativa com durac¸ão variável (de minutos a semanas).
Conclusões: Com base na revisão da literatura, não é possível uniformemente especiﬁcar a
dose mais eﬁcaz e segura de lidocaína administrada por via intravenosa no tratamento
da  dor neuropática ou musculoesquelética. Quanto à eﬁcácia, a infusão intravenosa da
lidocaína como alternativa para o tratamento da dor crônica de etiologias diversas parece
bastante promissora, embora estudos adicionais necessitem ser realizados.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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hronic pain affects approximately 7% to 40% of the world
opulation.1 In Brazil, a study conducted by WHO,  in 1998,
howed a prevalence of 31% (data from Rio de Janeiro);2 on the
ther hand, in Salvador, Bahia, it is estimated that 41.4% of the
opulation suffers from chronic pain.1
Pain is a public health problem,3–5 greatly impairing the
uality of life. Several factors, such as depression, sleep dis-
urbances, difﬁculty concentrating, hopelessness, feelings of
eath and others, are associated with this symptom. The loss
f quality of life is a fact, as the pain begins to guide and limit
he behavior and activities of the subject, generating social
ithdrawal, changes in sexuality, changes in family dynam-
cs and economic imbalance.3 Nearly 80% of patients with
hronic pain reported that their pain interferes in activities of
aily living, and two thirds said that the pain causes negative
mpact on personal relationships.6 Physical and functional
isability, whether temporary or permanent, jeopardizes the
rofessional activity7 and causes work absenteeism, increas-
ng the costs of health systems.5 In the United States, for
xample, it is estimated that over 50 million working days are
ost each year.8 Thus, chronic pain is an important medical
nd social problem, and opioid abuse is of great concern, due
or the problems stemming from their multiple side effects,
ncluding addiction.
Often the complexity of the pathophysiological mecha-
isms that explain the initiation and maintenance of painmakes difﬁcult the assessment, diagnosis and treatment of
pain syndromes that may present inﬂammatory, neuropathic
or mixed components. Thus, there are several classes of
drugs used in the treatment of chronic pain patients, in
an attempt to reduce the intensity of pain and improve
their quality of life. Among the local anesthetics, lidocaine
[2-(diethylamino)-N-(2,6 dimethylphenyl) acetamide], a weak
base with antiarrhythmic properties,9 has been used by vari-
ous routes, including intravenous.
Lidocaine alters the transmembrane conductance of
cations, especially sodium, potassium and calcium, both in
neurons and myocytes.10 Voltage-dependent sodium chan-
nels constitute its classical targets, and the afﬁnity of the
drug for the channel is greater when it is opened (activated
or inactive).9 Thus, the degree of blocking varies according
to the neuronal stimulation frequency.6,11 However, other
mechanisms are also involved in the analgesia provided by
lidocaine9,12 as, for instance, the interaction, whether direct or
indirect, with different receptors and pathways of nociceptive
transmission, like the muscarinic agonists, glicine inhibitors,
release of endogenous opioids and of adenosine triphosphate,
and the reduced production of excitatory amino acids, neu-
rokinins and thromboxane A2.12
Although lidocaine is typically administered through local
injections, it is also used intravenously for various purposes,
such as regional anesthesia, as an anti-dysrhythmic agent,
in the relief of peripheral and central neuropathic pain,13,14
ﬁbromyalgia treatment15 and as an adjuvant in postoperative
pain,9 among others.
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For these reasons, lidocaine is used in the treatment of
patients with ﬁbromyalgia, arthrosis, cancer, postherpetic
neuralgia, neuropathic pain, and of patients with several other
disorders causing chronic pain. Although control of chronic
pain is difﬁcult, many  efforts have been directed towards the
development of increasingly effective treatments, especially
pharmacological ones, in reducing the intensity of pain in
these patients and in providing longer periods of analgesia.
The aim of this review is to analyze, based on the literature,
the analgesic effect of lidocaine administered intravenously
for the treatment of chronic pain. The method adopted was
to review the literature, consisting in the search for sci-
entiﬁc articles, in this case, on the efﬁcacy of intravenous
lidocaine infusion in the treatment of patients with chronic
pain. To this end, bibliographic databases, such as CENTRAL,
MEDLINE/PubMed, LILACS and SciELO were searched. In the
searching strategy, we  used the following keywords
“lidocaine”, “intravenous and chronic pain”, or also “lido-
caine, infusion and chronic pain”. Another strategy was a
manual search in reference lists of those identiﬁed and
selected articles by electronic search. We  used as criteria
for selecting the studies: publications until December 2012,
with designs of the randomized clinical trial on humans type,
which have been published in Portuguese or English, exclud-
ing other languages. Articles of relevance to lidocaine, as well
as on disorders that present with chronic pain, were also
included. Studies which evaluated the efﬁcacy of lidocaine
in relieving only evoked pain in animals, or that evaluated
the efﬁcacy of lidocaine with another drug, were discarded
(exclusion criteria).
Intravenous  lidocaine  in  the  treatment  of
chronic  pain  conditions
Fibromyalgia
Several studies suggest that intravenous lidocaine can reduce
the pain associated with ﬁbromyalgia, although this is a
condition refractory to other analgesic drugs. In a double-
blind placebo-controlled trial conducted in the 90s, there
was a decrease in pain scores during and after infusion of
lidocaine.15 This ﬁnding is conﬁrmed by subsequent stud-
ies, in that the duration of relief exceeded both the infusion
time as the half-life of the drug.15 In an uncontrolled
trial, ﬁve consecutive infusions of intravenous lidocaine
with increasing doses of 2 mg/kg to 5 mg/kg resulted in
a reduction in pain scores that was signiﬁcant after the
ﬁfth day and persisted after 30 days.15 In another study,
the reduction in pain scores was also maintained even 30
days after the last infusion of lidocaine.15 In a double-
blind crossover trial involving 75 patients with ﬁbromyalgia,
a lasting analgesic effect of the drug was conﬁrmed.15
On the other hand, other studies did not achieve posi-
tive results after the intravenous lidocaine infusion: after
four infusions of the drug at weekly intervals, the observed
16reduction in pain scores was not statistically signiﬁcant.
In another study, which combined 3 mg/kg of intravenous
lidocaine administered weekly with 25 mg  of amitriptyline
for 4 weeks, there was no change in pain intensity in 0 1 4;5 4(5):386–392
patients with ﬁbromyalgia, when compared with amitripty-
line monotherapy.17
Myofascial  pain  syndromes
Most studies on intravenous lidocaine were performed in
patients with neuropathic pain, while myofascial pain carri-
ers are generally tested with an intramuscular infusion of the
drug. In a study carried out in 2005, which involved infusions
of lidocaine, ketamine and morphine, among 30 patients with
chronic pain associated with whiplash lesion (cervical deceler-
ation injury), 11 of 18 responders experienced pain reduction
after lidocaine infusion at a dose of 5 mg/kg.18
Neuropathic  pain
Peripheral  neuropathies
Wallace et al. achieved signiﬁcant analgesia in plasma concen-
trations of lidocaine between 1.5-2.5 mg/mL. In another study,
a reduction in VAS score for continuous pain occurred when
lidocaine was infused at high (5 mg/kg) and low (1 mg/kg)
doses for periods of two hours or more.  However, there were
no differences in comparison with placebo.19
In the trial by Ferrante et al., the infusion of intravenous
lidocaine demanded about ﬁve minutes to achieve maximal
analgesia, and the analgesia increased abruptly from a cer-
tain plasma concentration (0.62 g/mL).20 In other studies, the
effect began 30 minutes after starting the infusion, reaching
the peak effect within 60 to 120 minutes.21,22 In addition, there
was signiﬁcant analgesia compared to placebo for more  than
6 hours after infusion, and a subset of patients reported relief
for a still longer period, greater than 7 days.21
Reduction in pain intensity was also reported in patients
with postherpetic neuralgia. The drug infusion at doses of
5 mg/kg or even 1 mg/kg for varying periods caused a signiﬁ-
cant reduction in pain scores,6 without, however, establishing
a correlation between relief and plasma concentrations of the
drug.
In patients with painful diabetic neuropathy, the duration
of the individual effect varied between 3 and 28 days at doses
of 5 or 7.5 mg/kg infused over a period up to 4 hours,23,24 with
a trend to a greater response to lidocaine 7.5 mg/kg compared
to 5 mg/kg, but this difference did not reach signiﬁcance. The
qualitative nature of pain was signiﬁcantly modiﬁed by the
drug, compared with placebo.24
Although several studies conﬁrm the efﬁcacy of lidocaine
on continuous spontaneous pain caused by peripheral nerve
injury, other experiments have failed to accordingly reafﬁrm
the beneﬁcial effect of the drug. A trial conducted in 2006,
for example, demonstrated a signiﬁcant reduction in pain
evoked by repetitive stimuli, but not in spontaneous pain, after
the infusion of 5.0 mg/kg for 30 minutes.25 The same negative
result was observed by Gormsen et al.26 In a study comparing
the effect of lidocaine with ketamine and placebo, lidocaine
2.5 mg/kg was not enough to generate signiﬁcant differences
versus placebo or ketamine. However, after the end of the
infusion, patients who responded to lidocaine experienced a
period of greater pain relief than patients who  responded to
ketamine, whose VAS scores virtually returned to pre-drug val-
ues after the end of infusion.27 Another experiment that used
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ncreasing doses of the drug (1, 3 and 5 mg/kg) also failed to
how analgesic effect of lidocaine at low doses, proving its
ffectiveness only at the highest concentration.28
Lidocaine doses between 1.5 and 5.0 mg/kg proved effective
o suppress ectopic discharge without blocking nerve con-
uction, corresponding to plasma levels of 0.62 to 5.0 mg/mL.
urthermore, the effect of systemic lidocaine on neuropathic
ain may be different, depending on the source causing the
ain. Thus, its effectiveness may be greater in patients with
eripheral nerve injury than in those with pain due to damage
o the central nervous system or of unknown etiology.29
In cases of complex regional pain syndrome (CRPS), the use
f intravenous lidocaine was reported to be beneﬁcial in some
atients when studied retrospectively, both in adults and in
hildren.30,31 Controlled studies, however, failed to conﬁrm
hese data. In an experiment that used a computer-controlled
nfusion pump, there was a signiﬁcant decrease in the scores
or spontaneous pain only when plasma lidocaine reached
he highest level (3 mg/mL); plasma levels of 1 and 2 mg/mL
id not cause a signiﬁcant effect on spontaneous pain, which
an be explained by the fact that this study involved intense
eurosensory testing, that may have masked the effect of the
rug.32
entral  pain
ystemically, lidocaine can induce signiﬁcant and selective
eduction of various components of pain caused by lesions of
he central nervous system, including spontaneous pain, and
wo of 16 patients had relief for over 45 minutes after an infu-
ion of 5 mg/kg of the active drug, compared with placebo.33
n another randomized, placebo-controlled trial, the drug alle-
iated neuropathic pain either below or at the level of the
pinal lesion.34 These results are opposite to those found in a
tudy carried out in 2004 in which only ketamine, and not lido-
aine, was shown to reduce spontaneous continuous pain in
atients with pain secondary to injury to the central nervous
ystem.6
The three aforementioned placebo-controlled studies
valuated the efﬁcacy of intravenous lidocaine in central neu-
opathic pain. Two of them, using high doses of the drug
5 mg/kg IV) and including a total of 32 patients with traumatic
pinal injury or syringomyelia, tested positive for spontaneous
ain (both at the level of the spinal injury and below it), while
he study using a smaller dose (1.5 mg/kg IV) had a negative
utcome.
The analysis of Table 1 demonstrates the lack of unifor-
ity of the studies in relation to the data presented: of the
8 articles analyzed, not all reported the dose of lidocaine or
he infusion time; just some of them made some measure-
ents of plasma concentration of the drug during infusion,
nd of those which did it, few reported the minimal plasma
evel in which there was effect. Although the occurrence of
dverse effects have been reported in most studies, some of
hem did not specify which reactions were observed. The vast
ajority of studies was limited to search the analgesic effect
f lidocaine shortly after the infusion or, at most, a few hours
ater, refraining from investigating whether there was pro-
onged relief, a critical factor in patients with chronic pain.
mall sample size was a common limitation of many  of the
tudies reviewed, and, at least in one of them, a difference 4;5 4(5):386–392 389
between groups was generated (in terms of characteristics:
mean age and proportion of men  and women), despite the
random allocation.28
Two of the studies included in the review did not involve a
control group; however, the maintenance of a positive effect
for over 30 days after the last therapeutic intervention, as it
occurred in an experiment conducted by Schafranski et al.,
makes unlikely a placebo effect.15 Conversely, a controlled
study failed to demonstrate the analgesic efﬁcacy of lidocaine
in ﬁbromyalgia patients, because the reduction in pain scores
did not reach statistical signiﬁcance, although more  impor-
tant reliefs have been obtained in the group receiving the drug,
compared to placebo.16
According to most studies reviewed, the lasting effect
would be obtained after repeated infusions of the drug,
although the possibility of relief after a single infusion could
not be ruled out. Of the six experiments related to ﬁbromyal-
gia, only two have not conﬁrmed the analgesic power of
intravenous lidocaine, having strong evidence of its efﬁcacy
for pain control in these patients.
With regard to musculoskeletal pain, the positive effects
of drugs tend to be poor and generally do not improve sig-
niﬁcantly the patients’ disability nor quality of life, despite
the pain relief produced.20 Thus, a greater number of studies
to evaluate the effect of systemic lidocaine in these patients
to determine its actual usefulness and effectiveness is still
needed.
Boas et al. reported a reduction of pain by deafferenta-
tion and of central pain with the use of intravenous lidocaine,
indicating a possible therapeutic value of this route for lido-
caine in the management of intractable neuropathic pain
syndromes.35 Since then, several studies have demonstrated
that systemic lidocaine may be effective in treating various
disorders that present with neuropathic pain, at doses that do
not produce frank anesthesia and in plasma concentrations
below those required to block axonal conduction.23,35–38 The
analgesic effects of the drug may be observed in patients with
diabetic neuropathy, postherpetic neuralgia and in several
neuropathic disorders, such as complex regional syndrome
type I and II and post-stroke pain.28
In cases of peripheral neuropathic pain, plasma concen-
trations of lidocaine between 1.5-2.5 mg/mL  appear sufﬁcient
to promote analgesia.29 However, there is evidence that the
duration of exposure can be more  important than the dose
itself, leading to a reduction in VAS score for continuous pain
after infusion of high (5 mg/kg) and low (1 mg/kg) doses of lido-
caine for periods of two hours or more,  although there was no
difference from placebo.39 The fact that lidocaine has reached
maximum analgesia within ﬁve minutes after the start of infu-
sion, with an abrupt increase in its analgesic effect after a
certain plasma concentration (0.62 g/mL), suggests that its
effect by venous route does not accompanies a dose-effect
curve, suddenly blocking the painful stimulus.40
Although the half-life of the drug is only 120 minutes, the
analgesia provided by systemic lidocaine is prolonged, maybe
extending over days or even weeks.21 This may be due to the
action of intravenous lidocaine in the peripheral and central
nervous system. It is known that neuromata formed at sites
of injury to peripheral nerves have an abnormal accumula-
tion of sodium channels, which should be a big contributor
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Table 1 – Revised articles’ data.
Author(s)/year Sample size
(cases/controls)
Test type
(crossover/
parallel/open)
No. of
infusions of
lidocaine
Infusion for
each dose
Infusion
time
Signiﬁcant
relief  compared
to placebo
Wallace et al., 199629 11 (11/11) Crossover 1 ****  **** Yes
Baranowski et al., 199939 24 (24/24) Crossover 2 1 and 5 mg/kg 2 h No
Attal et al., 200033 16(16/16) Crossover 1 5 mg/kg 30 min Yes
Finnerup et al., 200543 24 (13/11) Crossover 1 5 mg/kg 30 min Yes
Lemming et al., 200518 33 (missing data) Crossover 1 5 mg/kg 30 min Yes
Tremont-Lukats et al.,  200628 32 (7/9/8/8) Parallel 1 1, 3 e 5 mg/kg 6 h Yes (higher dose)
Attal et al., 200421 22 (22/22) Crossover 1 5 mg/kg 30 min Yes
Wallace et al., 200032 16 (16/16) Crossover 1 **** **** Yes
Gottrup et al., 200625 20 (10/10) Crossover 1 5 mg/kg 30 min No
Vlainich et al;, 201017 30 (15/15) Parallel 4 3 mg/kg 60 min No
Schafranski et al., 200915,* 23 Open 5 2-5 mg/kg 2 h Yes
Kastrup et al., 198723 15 (8/7) Crossover 1 5 mg/kg 30 min Yes
Kvarnström et. al., 2003/20046,27 10 (10/10) Crossover 1 2,5 mg/kg 40 min No
Ferrante et al., 199640,* 13 Open 1 500 mg 60 min Yes
Gormsen et al., 200926 15 (15/13) Crossover 1 5 mg/kg 4 h No
Viola et al., 200624 15 (15/15/15) Crossover 2 5 e 7,5 mg/kg 4 h Yes
Wu et al.,  200222 32 (11/11/12) Crossover 1 5 mg/kg 42 min No
Author(s)/year Reduction of
pain (%)
No. of patients
who reported relief
in each group
(cases/controls)
Duration
of effect
Plasma
concentration
at which there
was relief
Adverse effects Jadad score
Wallace et al., 199629 >50 ****  **** 1,5-2,5 g/mL Delirium, nausea 2
Baranowski et al., 199939 ∼50 (1 mg/kg)
and >30 (5 mg/kg)
****  **** 1,7 g/mL Perioral
paraesthesia
(higher dose)
2
Attal et al., 200033 ∼50 10/6 45 min **** **** 4
Finnerup et al., 200543 >30 19/4 **** 1,5-4,1 g/mL Delirium, dizziness,
drowsiness, dysarthria,
blurred vision, tremors,
dry mouth, headache.
5
Lemming et al., 200518  **** 11/2 ****  **** **** 5
Tremont-Lukats et al.,
200628
>30 **** 6 h **** Delirium,
nausea/vomiting, diplopia,
headache, tinnitus,
perioral paresthesia,
metallic taste, tightness in
throat.
5
Attal et al., 200421 >60 11/**** 6 h **** Delirium, drowsiness,
perioral numbness,
truncated speech,
dizziness, dysarthria.
5
Wallace et al., 200032 ≥25 ****  **** 3 g/mL Delirium 2
Gottrup et al., 200625 ∼10 4/0 ****  **** Delirium, nausea,
paresthesia, blurred
vision, dizziness,
dysarthria, headache, dry
mouth.
4
Vlainich et al;, 201017 >45 ****  ****  **** **** 4
Schafranski et al., 200915,* >15and >10 (after
30 days)
**** 30 days **** No adverse effects Not
applicable
Kastrup et al., 198723 >40 (1-3 days) and >15 9/4 3-21 days **** **** 2
Kvarnström et. al.,
2003/20046,27
∼10 (>50 in 1 patient) 1/0 **** **** Drowsiness, perioral
paresthesia.
4
Ferrante et al., 199640,* 100 (100
patients), 62, 55
and 40 (the other)
13 **** 0,62 g/mL **** Not
applicable
Gormsen et al., 200926 ∼36 11/8 ****  **** Drowsiness, perioral
paresthesia, headache,
dizziness, fatigue,
discomfort, dry mouth,
nausea, muscle spasms.
5
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Table 1 (Continued ).
Author(s)/year Reduction of
pain (%)
No.  of patients who
reported relief in
each group
(cases/controls)
Duration
of  effect
Plasma
concentration at
which there was
relief
Adverse effects Jadad score
Viola et al., 200624 **** **** 28 days **** Delirium (higher dose) 3
Wu et al.,  200222 ∼30 ****  **** **** **** 4
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∗∗∗ Missing data.
o the severe pain produced by such lesions.14,41 The central
yperalgesia, on the other hand, is related to sodium chan-
els located at the ends of mechanoreceptors, in the spinal
ord, and in dorsal root ganglia.12 The blocking of such sodium
hannels cause inhibition of the spontaneous and evoked neu-
onal activity and reduces the neuronal hyperactivity, with
reater pain relief and for a longer time, compared with
hat related to the drug’s pharmacokinetic patterns. Lidocaine
lso promotes the reduction of allodynia and hyperalgesia. A
ecrease in spontaneous pain, dysesthesia, mechanical hyper-
lgesia and mechanical allodynia occurs.9
In addition to its well established anesthetic and antiar-
hythmic actions, intravenous lidocaine also has signiﬁcant
nti-inﬂammatory properties, by inhibiting the release of
ytokines and interfering with the action of inﬂammatory
ells, such as macrophages, monocytes and polymorphonu-
lear cells.9,12,42 This latter form of action is being currently
ested in several studies and seems very promising.
In patients with painful diabetic neuropathy, lidocaine can
educe spontaneous activity in small myelinated ﬁbers by
tabilizing the damaged nerve membrane; this has been pro-
osed as the cause of neuropathic pain.23 Furthermore, the
ffect of systemic lidocaine on neuropathic pain may be dif-
erent, depending on the source of pain generation. Thus, its
ffectiveness may be greater in patients with peripheral nerve
njury than in those with pain due to damage to the CNS or of
nknown etiology.29
In the study by Viola et al. (2006), there was a trend for a
reater response to lidocaine in doses of 7.5 mg/kg compared
ith 5 mg/kg, but without statistical signiﬁcance.24 This result
ay indicate that the doses examined were near the top of the
ose-response curve for this therapy. Although several studies
onﬁrm the efﬁcacy of lidocaine in cases of continuous spon-
aneous pain caused by peripheral nerve injury, other trials
ailed to accordingly reafﬁrm the beneﬁcial effect of the drug.
The literature suggests that, in fact, intravenous lidocaine
s effective in the management of chronic pain. Ten of the
4 studies in patients with peripheral neuropathies obtained
avorable outcomes with the systemic use of the drug in the
reatment of diseases with neuropathic pain, including pos-
herpetic neuralgia and painful diabetic neuropathy. The four
emaining studies failed to demonstrate the analgesic effect of
idocaine, most likely due to methodological issues, for exam-
le, insufﬁcient numbers of patients,26 or even the production
f evoked pain shortly after the start of infusion, masking
ossible positive results.25
In patients with CNS injury, lidocaine relieved neuropathic
ain either below or at the level of the spinal lesion, suggestingan effect on the generating mechanisms of central pain,
although it is not possible to determine whether the effect
occurs at the spinal or brain level.43
The lidocaine dose used by several investigators varies,
most often from 1 to 5 mg/kg, administered over a period
of 30 to 60 minutes. In several randomized clinical trials,
researchers measured the plasma levels of the drug in
an attempt to ﬁnd a relationship between concentration
and response.32,40 Although some authors state that the
minimum plasma concentration able to produce signiﬁcant
analgesia is 1.5 mL/L (achieved with 2-5 mg/kg infused over
30-60 minutes),22 no information on the speciﬁc therapeutic
concentration is available.
Conclusion
The intravenous infusion of lidocaine as an alternative for the
treatment of chronic pain of various etiologies seems to be
very promising, but further studies need to be performed.
Regarding the neuropathic or musculoskeletal pain, it is
not possible to uniformly specify the most effective and safe
dose of intravenous lidocaine to be used in its treatment.
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